Mode
Text Size
Log in / Sign up

Hyperuricemia

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hyperuricemia

11 trials tracked for Hyperuricemia: 2 in phase 3 or 4.

11Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 6 Other / NA 3
  1. Phase 4 The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Completed
  2. Phase 3 Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Completed
  3. Phase 2 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia Completed
  4. Phase 2 Lowering Serum Uric Acid to Prevent Acute Kidney Injury Completed
  5. Phase 2 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Completed
  6. Phase 2 Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid Completed
Show 5 more trials
  1. Phase 2 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid Completed
  2. Phase 2 Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia. Completed
  3. N/A Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status Completed
  4. N/A The Diet Gout Trial Completed
  5. N/A Magnetic Resonance Imaging in Subjects With Gouty Tophi Completed

Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Hyperuricemia

How can I predict my risk of developing hyperuricemia while living with HIV?

Your risk of hyperuricemia with HIV can be predicted using baseline serum uric acid level and CD4+ count, as shown in a 2026 risk model [8].

Full answer →